会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 21. 发明授权
    • Certain triphenylphosphinimide derivatives
    • 某些三苯基膦酰亚胺衍生物
    • US4894368A
    • 1990-01-16
    • US207846
    • 1988-06-17
    • Andrew S. TomcufcikJohn E. EmmaNancy H. EudyJoseph W. MarsicoHoward Newman
    • Andrew S. TomcufcikJohn E. EmmaNancy H. EudyJoseph W. MarsicoHoward Newman
    • C07F9/535
    • C07F9/5355
    • Novel triarylphosphinimide derivatives having the formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are each at the ortho or meta position, represent mono- or disubstituents and are selected from the group consisting of hydrogen, alkyl(C.sub.1 -C.sub.3), alkoxy(C.sub.1 -C.sub.3), trifluoromethyl and halogen; and R.sub.4 is selected from the group consisting of alkyl (C.sub.1 -C.sub.3), alkenyl(C.sub.2 -C.sub.3), alkynyl(C.sub.2 -C.sub.4), alkynyl(C.sub.2 -C.sub.4), cycloalkyl(C.sub.3 -C.sub.5), cycloalkyl(C.sub.3 -C.sub.6)methyl, 4-oxopentyl, 3-tetrahydrofuranyl, 2,3-dihydro-1H-iden-1-yl, 1-alkyl(C.sub.1 -C.sub.3)cyclopentyl, trans-2-alkyl(C.sub.1 -C.sub.3)cyclopentyl, trans-2-alkoxy(C.sub.1 -C.sub.3)cyclopentyl, 1-cyclopropylethyl, 2-methylcyclopropylmethyl, dicyclopropylmethyl, 2-, 3- or 4-pyridinylmethyl, 2-cyclopenten-1-yl, tetrahydro-2H-pyran-4-yl and cis and trans-2-methoxycyclohexyl; with the proviso that when R.sub.4 is alkyl(C.sub.1 -C.sub.3), R.sub.1, R.sub.2 and R.sub.3 may not each be hydrogenor ##STR2## wherein R.sub.1, R.sub.2 and R.sub.3 are each at the ortho or meta position and are selected from hydrogen and alkyl(C.sub.1 -C.sub.3), and X is an acid addition salt; processes for producing them, compositions containing them, and methods for using them in mammals to effect diuresis; to lower plasma renin levels and to increase cardiac contractility.
    • 具有式“IMAGE”的新型三芳基膦酰亚胺衍生物,其中R 1,R 2和R 3各自为邻或间位,代表单取代或未取代的,并且选自氢,烷基(C1-C3),烷氧基(C1- C3),三氟甲基和卤素; (C 2 -C 4),炔基(C 2 -C 4),环烷基(C 3 -C 5),环烷基(C 3 -C 6) 甲基,4-氧代戊基,3-四氢呋喃基,2,3-二氢-1H-己烯-1-基,(C1-C3)环戊基,反式-2-烷基(C1-C3)环戊基,反式-2- 烷氧基(C1-C3)环戊基,1-环丙基乙基,2-甲基环丙基甲基,二环丙基甲基,2-,3-或4-吡啶基甲基,2-环戊烯-1-基,四氢-2H-吡喃-4-基和顺式和反式 - 2-甲氧基环己基; 条件是当R 4是烷基(C 1 -C 3)时,R 1,R 2和R 3可以不是氢或者其中R 1,R 2和R 3各自在邻位或间位,并且选自氢和烷基( C1-C3),X是酸加成盐; 生产它们的方法,含有它们的组合物,以及在哺乳动物中使用它们以产生利尿的方法; 降低血浆肾素水平并增加心脏收缩力。
    • 22. 发明授权
    • 10,10-dihydro-10-[(substituted-carbonyl)imino]-10-phe
nyl-10H-phenoxaphosphines
    • 10,10-二氢-10- [(取代羰基)亚氨基] -10-苯基-10H-苯氧基膦
    • US4777290A
    • 1988-10-11
    • US61981
    • 1987-07-27
    • Andrew S. TomcufcikJoseph W. MarsicoNancy H. EudyHoward Newman
    • Andrew S. TomcufcikJoseph W. MarsicoNancy H. EudyHoward Newman
    • C07F9/6571C07F9/02
    • C07F9/657163
    • Novel 10,10-Dihydro-10-[(substituted carbonyl)imino]-10-phenyl-10H-phenoxaphines of the formula: ##STR1## wherein A is selected from the group consisting of hydrogen and COOR.sub.1, where, when A is hydrogen the compound is in the form of a water soluble salt HnX, where n is an integer 1 or 2 and X is selected from the group consisting of sulfate, trefluoroacetate, bromide and chloride and R.sub.1 is selected from the group consisting of straight or branched chain alkyl(C.sub.1 -C.sub.4), alkenyl(C.sub.2 -C.sub.4), alkynyl(C.sub.2 -C.sub.4), cycloalkyl(C.sub.3 -C.sub.6), cycloalkyl(C.sub.3 -C.sub.6)methyl, benzyl, pyridylmethyl and tetrahydro-3-furanyl; methods for using these compounds for effecting diuresis, treating hypertension and edema and lowering plasma renin activity in mammals; pharmaceutical compositions of matter containing these compounds and processes for their preparation.
    • 新的10,10-二氢-10- [(取代羰基)亚氨基] -10-苯基-10H-吩恶嗪,其结构式如下:其中A选自氢和COOR1,其中当A为氢时 该化合物为水溶性盐HnX的形式,其中n为整数1或2,X选自硫酸盐,三氟乙酸盐,溴化物和氯化物,R1选自直链或支链 烷基(C1-C4),烯基(C2-C4),炔基(C2-C4),环烷基(C3-C6),环烷基(C3-C6)甲基,苄基,吡啶基甲基和四氢-3-呋喃基; 使用这些化合物进行利尿,治疗高血压和水肿以及降低哺乳动物血浆肾素活性的方法; 含有这些化合物的物质的药物组合物及其制备方法。
    • 28. 发明授权
    • 3-heteroalkyl-2,4-quinzaolinediones
    • 3-杂烷基-2,4-喹唑啉二酮
    • US4684654A
    • 1987-08-04
    • US765417
    • 1985-08-14
    • William B. Wright, Jr.Andrew S. Tomcufcik
    • William B. Wright, Jr.Andrew S. Tomcufcik
    • C07D401/06C07D521/00A61K31/505C07D403/06
    • C07D231/12C07D233/56C07D249/08C07D401/06
    • Compounds of the formula: ##STR1## wherein A is a divalent moiety of the formula:--C.sub.n H.sub.2n -- --CH.sub.2 CH.dbd.CHCH.sub.2 --or ##STR2## wherein n is an integer from 2-10, inclusive; R is hydrogen or alkyl having from one to four carbon atoms; R.sub.1 and R.sub.2 may be the same or different and may be selected from the group consisting of hydrogen, halogen, trifluoromethyl, alkoxy having from one to four carbon atoms, alkyl having from one to four carbon atoms, nitro and amino; wherein Heteroaryl is ##STR3## wherein R.sub.3 and R.sub.4 may be selected from hydrogen, alkyl having from one to four carbon atoms, or phenyl; and X is CH or N, together with the pharmaceutically acceptable salts thereof, which act as thromboxane synthetase inhibitors and hypotensive agents; methods for their production and use.
    • 下式的化合物:其中A是下式的二价部分:-C n H 2n--CH 2 CH = CHCH 2 - 或其中n是2-10的整数,包括端值; R是氢或具有1-4个碳原子的烷基; R 1和R 2可以相同或不同,并且可以选自氢,卤素,三氟甲基,具有1-4个碳原子的烷氧基,具有1至4个碳原子的烷基,硝基和氨基; 其中杂芳基是其中R 3和R 4可以选自氢,具有1至4个碳原子的烷基或苯基; 并且X是CH或N以及其药学上可接受的盐,其用作血栓烷合成酶抑制剂和降压药; 生产和使用方法。